Moving medical cannabis to Schedule III may expand research and access, but pharmacists need to be ready to counsel patients on drug interactions, cannabis use disorder, and psychiatric risks.
Mary Bridgeman, PharmD
Advertisement
Articles by Mary Bridgeman, PharmD
Advertisement
Latest Updated Articles
Allergy Cases in Self-CareApril 15th 2010
- OTC Case Studies: Ocular and Skin Disorders
May 11th 2010
Advertisement
Advertisement
Trending on Pharmacy Times
1
Beyond Prescription Volume: Measuring the Pharmacist’s Value
2
Medicare GLP-1 Bridge Runs Outside Part D and Pharmacy Teams Need a Different Workflow
3
FDA Approves Talazoparib With Enzalutamide for HRR-Mutated Metastatic Prostate Cancer
4
GLP-1 RAs, Finerenone, and CKD: Key Data From Kidney Week 2026
5